Page 584«..1020..583584585586..590600..»

Research and Markets: Cell Therapy – Technologies, Markets and Companies – 2013 Report

By Dr. Matthew Watson

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/4gllbg/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2012, and projected to 2022.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 285 of these are profiled in part II of the report along with tabulation of 272 alliances. Of these companies, 156 are involved in stem cells. Profiles of 70 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

Originally posted here:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - 2013 Report

To Read More: Research and Markets: Cell Therapy – Technologies, Markets and Companies – 2013 Report
categoriaUncategorized commentoComments Off on Research and Markets: Cell Therapy – Technologies, Markets and Companies – 2013 Report | dataJanuary 9th, 2013
Read All

Owner hopes stem cell therapy will get dog's life back

By JoanneRUSSELL25

REHOBOTH, Mass. --

A first of its kind procedure is being performed in Massachusetts Monday. Its a stem cell therapy on a dog.

"He can't get comfortable, can't lay down, because of the pain, so he sits up and stares at the wall all night, which is tough to watch," said Bob Cook, Bubbas owner.

Cook of Taunton is talking about his 2-year-old English Bulldog Bubba, who suffers from hip dysplasia.

He said his condition has gotten worse in the last several months. After doing research, he found out about a regenerative stem cell therapy and has been hopeful.

He brought Bubba to the Abbot Animal Hospital in Rehoboth.

"Hopefully we can give these animals relief and increase quality of life and their life span as well, said Dr. Ashraf Gomaa.

Gomaa is the only doctor in our area certified by MediVet America, the company that developed this technology.

After extracting fat from Bubba, it is processed in a machine that basically breaks down the cells to get to the healthy stem cells. The cells are then injected back into Bubba into the area of concern.

"Replacing the bad cells with new cells, pretty advanced technology," Gomaa said.

See the original post here:
Owner hopes stem cell therapy will get dog's life back

To Read More: Owner hopes stem cell therapy will get dog's life back
categoriaUncategorized commentoComments Off on Owner hopes stem cell therapy will get dog's life back | dataJanuary 8th, 2013
Read All

Celling Biosciences Hosts Austin Cell Therapy Symposium

By NEVAGiles23

AUSTIN, Texas, Jan. 8, 2013 /PRNewswire/ --On Friday, January 4th Celling Biosciences hosted the Austin Cell Therapy Symposium at the downtown Hilton to build awareness and provide a platform for physicians, scientists, policy makers and academia to discuss the impact of cell therapy on global healthcare and the opportunity for the local community in Central Texas. Cell therapy will revolutionize the landscape of medicine by providing viable and affordable treatment options across all disciplines of medicine without the controversy associated with embryonic stem cells.

The keynote speaker for the event was Dr. Arnold I. Caplan, Professor of Biology and Director of the Skeletal Research Center at Case Western Reserve University. Dr. Caplan has published over 390 papers and manuscripts and has long been supported by the National Institute of Health and other non-profit and for-profit agencies for his efforts in trying to understand the development, maturation and aging of cartilage, bone, skin and other mesenchymal cell tissues."I firmly believe that the research and development efforts going on today will change the future of medicine forever. We are only scratching the surface of the potential there is to treat different health issues with cell therapy. It takes a concerted effort by scientists, physicians and commercial entities for patients to ultimately enjoy the benefits. This type of platform provided by Celling Biosciences allows us to effectively progress forward," says Dr. Caplan.

Dr. Carl Gregory from the Texas A&M Regenerative Medicine Institute and Dr. Vivienne Rebel from UT Health Science Center San Antonio both represented local academia in Central Texas. The research being conducted and the recruitment of students trained in these programs are obvious reasons for Texans to keep supporting Governor Perry's efforts to make Texas a leader in the research and commercialization efforts of regenerative cell therapy. Both speakers are leading efforts for research that will one day lead to alternative healthcare options.

Dr. Philippe Hernigou, a leading orthopedic surgeon from France, presented his 20 years clinical experience working with cell therapy in his practice as University of Paris Chief of Orthopedics.Dr. Hernigou is well published in his clinical use of cell therapy and has treated over 2,500 patients utilizing autologous bone marrow derived cells to treat a wide range of orthopedic pathologies. Dr. Hernigou's research on the safety of cell therapy has been accepted and will be presented at the 2013 AAOS, a leading congress for orthopedic surgeons.

Clinicians were also represented by Dr. Scott Spann, an orthopedic surgeon at Westlake Hospital in Austin, who provides care to patients with spinal cord injury.Dr. Spann believes one day cell therapy will be a common option for patients suffering from debilitating health issues like spinal cord injury.A member of the audience and orthopedic surgeon, Dr. Christoph Meyer has been utilizing cell therapy in his practice for years and also believes it is the future of medicine. "Thanks to these efforts, physicians are benefiting from access to the growing body of research based medicine being established in the field of cellular therapy and regenerative medicine.As the technology is developed, it ultimately gives my patients the best care available and this event gives me the opportunity to discuss experiences with world leaders in cell therapy."

Healthcare is going through major changes and cell therapy is going to have many challenges ahead. Julian Rivera, legal healthcare specialist at the Brown McCarroll Law Firm, discussed the impact of the recent challenges in front of the Texas Medical Board which has adopted rules that work with the FDA to help keep Texas revolutionizing cell therapy.Mr. Rivera believes that the legal issues will take time but is optimistic about how the State of Texas has handled the challenges thus far.

"We are fortunate to have industry leaders joining us to discuss the future impact of cell therapy. We are proud to be Texans who are pioneering the way in the global healthcare market place for regenerative cell therapies. Celling Biosciences understands that the cell therapy market is in its infancy which is a key reason why we invest heavily on research and development with our teams of scientists, engineers and registered nurses providing physicians with proven cell centric technologies and techniques that collectively help to recreate the human body's biological environment. It is not about just providing cells to treat patients.We believe with the help of these thought leaders presenting today we will get closer to better understanding how to keep delivering safe, efficacious and cost effective therapies to patients," says Founder and CEO of Celling Biosciences, Kevin Dunworth.

About Celling BiosciencesCelling Biosciences is an Austin based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine.Celling's product-offering focuses on autologous adult stem cell therapy and the devices and services that compliment these procedures.For more information please visit: http://www.cellingbiosciences.com.

Read more:
Celling Biosciences Hosts Austin Cell Therapy Symposium

To Read More: Celling Biosciences Hosts Austin Cell Therapy Symposium
categoriaUncategorized commentoComments Off on Celling Biosciences Hosts Austin Cell Therapy Symposium | dataJanuary 8th, 2013
Read All

Elsevier Selected to Publish Cytotherapy: The Journal of Cell Therapy

By Dr. Matthew Watson

AMSTERDAM, January 7, 2013 /PRNewswire/ --

Official journal of the International Society for Cellular Therapy (ISCT) to be published by Elsevier beginning January 2013

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce that the International Society for Cellular Therapy (ISCT) has selected Elsevier to publish Cytotherapy: The Journal of Cell Therapy effective January 2013.

"Elsevier presented ISCT with unsurpassed reach into the global medical community, top class publishing services, and significant experience in this field. We are extremely confident that our collaboration with Elsevier will not only help Cytotherapy grow for the benefit of our members and readers, but also for the benefit of all scientists, technologists, regulators, manufacturing experts and others dedicated to translational development of safe and effective cell therapies," said ISCT President, Kurt Gunter, MD, FASCP.

Cytotherapy is a highly influential publication in the mainstream of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of these disciplines. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, doctors, and regulatory experts involved in cell processing and therapy.

Senior Editor of Cytotherapy, John Barrett, MD, commented, "What matters is ensuring that new peer-reviewed treatments, developments, and studies reach as many specialists working with cell therapies as possible. In this, I believe Elsevier offers an unrivaled opportunity to help the journal achieve this goal."

Glen Campbell, Executive Vice President at Elsevier added, "Cytotherapy is an established and reputable journal and we are honored that the International Society for Cellular Therapy selected Elsevier as their publishing partner. Together, we will ensure that this prestigious title develops further as the leading global forum and resource for developing and supporting innovative cellular therapies."

For more information go to: http://www.journals.elsevier.com/cytotherapy

About ISCT

ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. Since 1992, ISCT has been the leading global forum for developing and supporting innovative cellular therapies through communication, education and training. ISCT fosters international translational research, informs national and global regulatory framework development and harmonization, drives commercialization strategies, and educates principal investigators, lab directors, technologists, regulators and commercial stakeholders. http://www.celltherapysociety.org

Read more from the original source:
Elsevier Selected to Publish Cytotherapy: The Journal of Cell Therapy

To Read More: Elsevier Selected to Publish Cytotherapy: The Journal of Cell Therapy
categoriaUncategorized commentoComments Off on Elsevier Selected to Publish Cytotherapy: The Journal of Cell Therapy | dataJanuary 7th, 2013
Read All

Bioheart to Present at Cell Therapy for Cardiovascular Disease Conference in New York

By LizaAVILA

SUNRISE, Fla., Jan. 7, 2013 /PRNewswire/ --Bioheart, Inc. (BHRT.QB) will present an update on 12 years of clinical data on MyoCell for treating heart failure at the 8th Annual Conference on Cell Therapy for Cardiovascular Disease January 23-25th, 2013 @ Columbia University Medical Center - http://celltherapy.crf.org/register.html - Course Director, Warren Sherman, M.D.

(Logo: http://photos.prnewswire.com/prnh/20130107/FL37699LOGO )

Howard J. Leonhardt, Founder and Chief Technology Officer of Bioheart, will present data from clinical trials sponsored by the company since 2001.

In Phase II/III clinical trials stage in the U.S. for muscle stem cells for treating advanced heart failure, Bioheart's MyoCell is believed to be the only cell type able to create new contractile muscle in heart scar tissue.Phase II/III Part I interim results demonstrated 95.7 meters improvement in exercise capacity in Bioheart MyoCell patients over placebo (-4 meters) in a double blind randomized study.This compares to -4 meters for CHF drugs, 16 meters for CRT pacers, 53 meters for cardiac stem cells, 52 meters for adipose derived cells and 10 meters allogeneic bone marrow derived cells.

Leonhardt will also provide a look at new generation improvements brought forward to enhance cell transplantation by Bioheart which include:SDF-1 gene transfection, electrical stimulation see http://www.myostimpacers.com, repeat injections, and nutrient hydrogel.

Founded in 1999, Bioheart is one of the original cell therapy companies.Since that time, more than 400 heart failure patients have been enrolled in various myoblast therapy clinical trials worldwide. 84% percent of Bioheart MyoCell treated patients have improved while only 16% have worsened. In placebo and control groups 69% of patients have worsened.

130 more patients are needed to complete the randomized, double blinded, placebo controlled MARVEL trial.MyoCell is a muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

View original post here:
Bioheart to Present at Cell Therapy for Cardiovascular Disease Conference in New York

To Read More: Bioheart to Present at Cell Therapy for Cardiovascular Disease Conference in New York
categoriaUncategorized commentoComments Off on Bioheart to Present at Cell Therapy for Cardiovascular Disease Conference in New York | dataJanuary 7th, 2013
Read All

Genetic Engineering and the GMO Industry: Corporate Hijacking of Food and … – Center for Research on Globalization

By Dr. Matthew Watson

Genetic Engineering and the GMO Industry: Corporate Hijacking of Food and ...
Center for Research on Globalization
“I recognized my two selves: a crusading idealist and a cold, granitic believer in the law of the jungle” – Edgar Monsanto Queeny, Monsanto chairman, 1943-63, “The Spirit of Enterprise”, 1934. When rich companies with politically-connected lobbyists ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHBpIWB0F14kM2lOuK2nNBgP8ZF1g&url=http://www.globalresearch.ca/genetic-engineering-and-the-gmo-industry-corporate-hijacking-of-food-and-agriiculture/5317339

To Read More: Genetic Engineering and the GMO Industry: Corporate Hijacking of Food and … – Center for Research on Globalization
categoriaUncategorized commentoComments Off on Genetic Engineering and the GMO Industry: Corporate Hijacking of Food and … – Center for Research on Globalization | dataJanuary 6th, 2013
Read All

Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as … – PR Newswire (press release)

By Dr. Matthew Watson

Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as ...
PR Newswire (press release)
Ms. Allen offers 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. For the past two years, she has provided independent consulting services to biotechnology companies in a variety ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFR9lc9-ACcxEG1QPGzCLM_NGj2cQ&url=http://www.prnewswire.com/news-releases/zafgen-appoints-20-year-biotechnology-industry-veteran-patricia-allen-cpa-as-chief-financial-officer-185643452.html

To Read More: Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as … – PR Newswire (press release)
categoriaUncategorized commentoComments Off on Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as … – PR Newswire (press release) | dataJanuary 6th, 2013
Read All

Market Report, "Tamir Biotechnology, Inc. – Product Pipeline Review – 2012 … – SBWire (press release)

By Dr. Matthew Watson

Market Report, "Tamir Biotechnology, Inc. - Product Pipeline Review - 2012 ...
SBWire (press release)
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Tamir Biotechnology, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Tamir Biotechnology ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEk0M23cyudgIHQDO_0jadkUz7gJg&url=http://www.sbwire.com/press-releases/market-report-tamir-biotechnology-inc-product-pipeline-review-2012-published-191286.htm

To Read More: Market Report, "Tamir Biotechnology, Inc. – Product Pipeline Review – 2012 … – SBWire (press release)
categoriaUncategorized commentoComments Off on Market Report, "Tamir Biotechnology, Inc. – Product Pipeline Review – 2012 … – SBWire (press release) | dataJanuary 6th, 2013
Read All

Cell Therapy Blog welcomes 2013

By Dr. Matthew Watson


Happy new year to all our readers.  We look forward to our interactions throughout 2013. This month watch for:
We look forward to seeing you on the 2013 conference circuit.  For a complete and current list of 2013 cell therapy industry conferences, click here.

We will be in San Francisco next week during EBD Biotech Showcase and JP Morgan as well as at the Phacilitate Cell and Gene Therapy Forum in Washington, DC at the end of the month.

As always we welcome your comments, feedback, criticisms, and questions.

Thank you for all for everything to contributed to and did to support this blog and our efforts this past year.  Let's have a great 2013!


p.s.  Don't forget to follow Cell Therapy Blog on Twitter @celltherapyblog 

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ABphTtPOrwo/cell-therapy-blog-welcomes-2013.html

To Read More: Cell Therapy Blog welcomes 2013
categoriaRegenerative Medicine commentoComments Off on Cell Therapy Blog welcomes 2013 | dataJanuary 6th, 2013
Read All

Presents at cell biology gathering – The Sunday Dispatch

By Dr. Matthew Watson

Presents at cell biology gathering
The Sunday Dispatch
Yurko hopes to earn a Ph.D. in biochemistry and molecular genetics and plans a career in biomedical research specializing in autoimmune and multi-drug resistant diseases. “I have found a way I can help people. It took me a while, but I now know it is ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGSShwKBPJtIH1sY5yg44TSjlIxHg&url=http://psdispatch.com/stories/Presents-at-cell-biology-gathering,248167?category_id%3D29%26town_id%3D4%26sub_type%3Dstories

To Read More: Presents at cell biology gathering – The Sunday Dispatch
categoriaUncategorized commentoComments Off on Presents at cell biology gathering – The Sunday Dispatch | dataJanuary 6th, 2013
Read All

Stem Cell Therapy for Autism, Mumbai, India – Video

By NEVAGiles23


Stem Cell Therapy for Autism, Mumbai, India

By: Rajeev Ranjan

View original post here:
Stem Cell Therapy for Autism, Mumbai, India - Video

To Read More: Stem Cell Therapy for Autism, Mumbai, India – Video
categoriaUncategorized commentoComments Off on Stem Cell Therapy for Autism, Mumbai, India – Video | dataJanuary 6th, 2013
Read All

Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost – Video

By LizaAVILA


Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost
stemcellmalaysia.com Stem cell therapy is not a cheap medical treatment. In fact, it is very expensive treatment to the majority of people. The high price of stem cell therapy becomes not only a deterrent to the majority but also creates room for non-medical sector to fill the void of demands for disease treatment. This video addresses the issues surrounding the cost of stem cell therapy, particularly in Malaysia. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.com

By: stemcells2012

Read more from the original source:
Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost - Video

To Read More: Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost – Video
categoriaUncategorized commentoComments Off on Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost – Video | dataJanuary 4th, 2013
Read All

Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.

By NEVAGiles23

Centagen has developed a breakthrough stem cell therapy that rejuvenates a patient's own adult stem cells. The Company has found a way to expand a patients own stem cells in the lab millions of times while rejuvenating the cells. For example, a patients blood pleuropotent stem cells could be rejuvenated and expanded in the lab and then re-injected to repair and rejuvenate organs and tissues damaged by aging or disease. Centagen has announced a funding campaign at http://www.indiegogo.com/centagen for additonal research and development.

Boulder, Colorado (PRWEB) December 31, 2012

Each of us has a limited supply of the kind of stem cells needed to rebuild, repair, and rejuvenate any part of our body. As we age, the supply and healing power of our stem cells diminishes. By providing a practically unlimited supply of one's own rejuvenated stem cells, we may keep people young and healthy for well over a century. In particular, regenerating tissues and organs prepared by expanding ones own stem cells could help with Alzheimers disease, diabetes, immune senescence, damaged heart tissue, arteriosclerosis, failing kidneys, failing hearing or eyesight, osteoporosis, weak muscles, and aged skin.

The technology requires no genetic engineering of the stem cells, so the procedure is much safer than the current procedures requiring genetic tampering. Only a patients adult stem cells are used, so there are no ethical issues common with embryonic stem cell use or side effects due to tissue rejection by your immune system.

Centagen has recently opened a crowd funding bid at http://www.indiegogo.com/centagen in concert with Maximum Life foundation, whose mission is to make 100 years old the new 50.

Forward-Looking Statements for Centagen, Inc.

This press release contains several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy of stem cell therapeutics. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors and the Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control. The Company may not update these forward-looking statements in a timely manner as conditions change.

Bryant Villeponteau, Ph.D. Centagen (877) 757-1923 Email Information

Link:
Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.

To Read More: Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.
categoriaUncategorized commentoComments Off on Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc. | dataDecember 31st, 2012
Read All

Stem Cell Therapy at IMC Dr.Omar Gonzalez – Video

By LizaAVILA


Stem Cell Therapy at IMC Dr.Omar Gonzalez
New Project 70

By: OmarGonzalezMD

Excerpt from:
Stem Cell Therapy at IMC Dr.Omar Gonzalez - Video

To Read More: Stem Cell Therapy at IMC Dr.Omar Gonzalez – Video
categoriaUncategorized commentoComments Off on Stem Cell Therapy at IMC Dr.Omar Gonzalez – Video | dataDecember 30th, 2012
Read All

Thursday Sector Leaders: Textiles, Biotechnology Stocks – Forbes

By Dr. Matthew Watson

Thursday Sector Leaders: Textiles, Biotechnology Stocks
Forbes
Also showing relative strength are biotechnology shares, up on the day by about 0.9% as a group, led by Synergy Pharmaceuticals DE (SGYP), trading up by about 7% and Astex Pharmaceuticals (ASTX), trading higher by about 6.9% on Thursday. comments ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGH1p_9R2w9gT1wd7nRShifo6Wknw&url=http://www.forbes.com/sites/marketnewsvideo/2012/12/27/thursday-sector-leaders-textiles-biotechnology-stocks/

To Read More: Thursday Sector Leaders: Textiles, Biotechnology Stocks – Forbes
categoriaUncategorized commentoComments Off on Thursday Sector Leaders: Textiles, Biotechnology Stocks – Forbes | dataDecember 30th, 2012
Read All

PU 121st Convocation Rulers cut educational budget from 2 to 1.5%: VC – Frontier Post

By Dr. Matthew Watson

PU 121st Convocation Rulers cut educational budget from 2 to 1.5%: VC
Frontier Post
Dr Akmal Rahim did his PhD in Botany while his wife Dr Farkhunda Jameel did her PhD in Molecular Biology and Molecular Genetics. Dr Saadat Ali and his wife Dr Ishrat Aziz did their PhDs in biological sciences. Dr Ans Nazar did his PhD in Islamic Studies.
Interesting facts at PU convocationThe News International

all 9 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHtUa7h4c2sHDRcLbVR1vQHKcKUzA&url=http://www.thefrontierpost.com/article/199766/

To Read More: PU 121st Convocation Rulers cut educational budget from 2 to 1.5%: VC – Frontier Post
categoriaUncategorized commentoComments Off on PU 121st Convocation Rulers cut educational budget from 2 to 1.5%: VC – Frontier Post | dataDecember 30th, 2012
Read All

Lessons from Prop 37 and the future of genetic engineering in agriculture – UC Berkeley (blog)

By Dr. Matthew Watson

Lessons from Prop 37 and the future of genetic engineering in agriculture
UC Berkeley (blog)
I was a strong opponent of Proposition of 37 and I am quite satisfied that it did not pass; but its failure serves more than vindication. It has interesting implications for the attitude of California on environmental issues, the future of GMOs, and ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNE1o0OhTpb1IXJ5t_J-bxUn0cbGqg&url=http://blogs.berkeley.edu/2012/12/20/lessons-from-prop-37-and-the-future-of-genetic-engineering-in-agriculture/

To Read More: Lessons from Prop 37 and the future of genetic engineering in agriculture – UC Berkeley (blog)
categoriaUncategorized commentoComments Off on Lessons from Prop 37 and the future of genetic engineering in agriculture – UC Berkeley (blog) | dataDecember 23rd, 2012
Read All

Delaware Biotechnology Institute hosts reception for IGERT Scholars – University of Delaware

By Dr. Matthew Watson


University of Delaware
Delaware Biotechnology Institute hosts reception for IGERT Scholars
University of Delaware
18, 2012--The Delaware Biotechnology Institute (DBI) hosted a reception Tuesday, Dec. 11, for the first cohort of five IGERT Scholars participating in the new National Science Foundation-supported Integrative Graduate Education and Research Traineeship ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHtdf56Z9ExA-NFNSKS3cKtmKWoyw&url=http://www.udel.edu/udaily/2013/dec/dbi-igert-scholars-121812.html

To Read More: Delaware Biotechnology Institute hosts reception for IGERT Scholars – University of Delaware
categoriaUncategorized commentoComments Off on Delaware Biotechnology Institute hosts reception for IGERT Scholars – University of Delaware | dataDecember 23rd, 2012
Read All

Burrill Starts Prana Biotechnology (PRAN) at Market Outperform – StreetInsider.com (subscription)

By Dr. Matthew Watson

Burrill Starts Prana Biotechnology (PRAN) at Market Outperform
StreetInsider.com (subscription)
The firm comments, "We are initiating coverage on Prana Biotechnology, that is developing a platform technology to address the potential causes of neurodegenerative disorders. Prana is undervalued relative to its peer group, in our view." "We believe ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFHEK_vUJ6_Ixz78W6JtjqLGddnMw&url=http://www.streetinsider.com/New%2BCoverage/Burrill%2BStarts%2BPrana%2BBiotechnology%2B(PRAN)%2Bat%2BMarket%2BOutperform/7962794.html

To Read More: Burrill Starts Prana Biotechnology (PRAN) at Market Outperform – StreetInsider.com (subscription)
categoriaUncategorized commentoComments Off on Burrill Starts Prana Biotechnology (PRAN) at Market Outperform – StreetInsider.com (subscription) | dataDecember 23rd, 2012
Read All

The Accuracy of Adipose Stem Cell Doses

By Dr. Matthew Watson

Tweet 


In August we published a blog post, "Are some cell counts too good to be true? Why some companies' product data may mislead", pointing people to a white paper released by INCELL Corporation.  That white paper appears now to have been pulled from their website (we are working to get a copy to make available again) but now they have published a paper providing more detailed data on aspects of their comparative cell count study.


The paper is introduced by the following abstract:

"Cell therapy products derived from adipose tissue have some unique processing issues with regard to obtaining accurate cell counts. This is because processing methods may not only show us the nucleated stromal vascular fraction (SVF) cells but also the micellular and microvesicle particles. This is true for both veterinary and human clinical products, and poses special concerns for in-clinic processing where the cell therapy dose is correlated with cell numbers and other QC data is not especially useful.

In this study, multiple cell counting methods were compared for SVF cell reparation that were derived from canine adipose tissue using commercially-available rocessing kits. The data clearly showed that many non-nucleated particles appear cell-like by size and shape, and can lead to counting errors with automated counters. In addition, certain reagents important to processing can have properties wherein the reagents alone (e.g., lecithin) may be counted as cells. The most accurate cell numbers were from hemocytometer-counting of cells stained with 4ยด,6-diamidino-2-phenylindole (DAPI) which shows the nuclei in concert with a viability stain such as trypan blue. The data clearly showed that care must be taken when counting cells used as a therapeutic dose."

This is an important issue particularly as it pertains to autologous cell-based treatments produced by point-of-care devices and/or kits.  I encourage you to read the paper.   

Morrison DG, Hunt DA, Garza I, Johnson RA, Moyer MP*. Counting and Processing Methods Impact Accuracy of Adipose Stem Cell DosesBioProcess J, 2012; 11(4): 4-17.

* Dr. Moyer is CEO and Chief Science Officer for INCELL Corporation, 12734 Cimarron Path, San Antonio, Texas 78249 USA. http://www.incell.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/z30UCNTkzIQ/the-accuracy-of-adipose-stem-cell-doses.html

To Read More: The Accuracy of Adipose Stem Cell Doses
categoriaRegenerative Medicine commentoComments Off on The Accuracy of Adipose Stem Cell Doses | dataDecember 23rd, 2012
Read All

Page 584«..1020..583584585586..590600..»


Copyright :: 2024